Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study

Chung, Bh H.; McQuarrie, K.; Bjartell, A.; Pereira de Santana Gomes, A. J.; Chowdhury, S.; Juárez Soto, Á.; Özgüroğlu, M.; de Santana Gomes, Aj Pereira; Given, R.; Merseburger, As S.; Miladinovic, B.; Soto, Á. Juárez; Uemura, H.; Li, N.; Hudgens, S.; Ye, D.; Floden, L.; Lopez-Gitlitz, A.; Chi, K. N.; Agarwal, N.

Published in

Elsevier, Annals of Oncology, (30), p. ix68, 2019

DOI: 10.1093/annonc/mdz424

Tools

Export citation

Search in Google Scholar

Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study

Journal article published in 2019 by Bh H. Chung, K. McQuarrie, A. Bjartell, A. J. Pereira de Santana Gomes, S. Chowdhury, Á. Juárez Soto, M. Özgüroğlu

, Aj Pereira de Santana Gomes, R. Given, As S. Merseburger, B. Miladinovic, Á. Juárez Soto, H. Uemura, N. Li, S. Hudgens and other authors.

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study